Healthcare Services

PDE inhibitors in drug development are influencing growth in the dyspnea market

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Dyspnea Market In 2026, And How Will Its Value Evolve By 2030?

The dyspnea market has shown significant expansion in recent years. Its valuation is expected to rise from $6.73 billion in 2025 to $7.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. This past growth can be attributed to factors like the prevalence of chronic respiratory diseases, the volume of hospital emergency admissions, smoking-related ailments, the increasing elderly population, and the impact of cardiopulmonary diseases.

The dyspnea market is anticipated to undergo significant growth in the upcoming years, with its valuation projected to reach $9.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This expansion within the forecast period can be primarily attributed to the rising demand for portable oxygen systems, developments in remote respiratory monitoring, personalized strategies for dyspnea management, the broadening of homecare services, and digital tools for symptom tracking. Prominent trends expected during this period encompass the increased deployment of oxygen therapy devices, a growing uptake of home-based respiratory care, an enhanced focus on symptom management therapies, the incorporation of breathing and relaxation practices, and improved methods for diagnosing respiratory conditions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/dyspnea-global-market-report

Which Primary Drivers Are Impacting The Dyspnea Market Growth?

The rising occurrence of respiratory illnesses is projected to fuel the expansion of the dyspnea market in the future. These illnesses are defined as conditions impacting the lungs and respiratory system, which obstruct airflow and diminish oxygen exchange. The increasing incidence of respiratory diseases stems from factors such as air pollution, smoking, environmental toxins, climate change, and heightened vulnerability among elderly demographics. The dyspnea market benefits from this trend as dyspnea acts as an essential indicator of compromised lung function, assisting medical professionals in diagnosing respiratory ailments, shaping treatment strategies, and observing disease progression. For example, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, COPD was responsible for 3.6% of the total disease burden and constituted 50% of the entire burden of respiratory diseases. Furthermore, in 2022, COPD was identified as the leading cause of 7,691 fatalities, with a death rate of 29.6 per 100,000 people, making up 4.0% of all deaths. Consequently, the growing prevalence of respiratory diseases is propelling the development of the dyspnea market.

What Are The Main Segments Within The Dyspnea Market Segment Structure?

The dyspnea market covered in this report is segmented –

1) By Treatment Type: Supplemental Oxygen Therapy, Relaxation Therapy

2) By Drug Class: Antianxiety, Antibiotics, Anticholinergic Agents, Corticosteroids, Other Drug Classes

3) By Route Of Administration: Oral, Inhalation, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Ambulatory Services, Other End Users

Subsegments:

1) By Supplemental Oxygen Therapy: Continuous Flow Oxygen Therapy, Pulse Dose Oxygen Therapy, Oxygen Concentrators, Portable Oxygen Cylinders

2) By Relaxation Therapy: Breathing Exercises, Meditation and Mindfulness, Progressive Muscle Relaxation, Biofeedback Therapy

Which Trends Are Shaping Growth In The Dyspnea Market?

Leading companies in the dyspnea market are concentrating on creating novel drug treatments, including phosphodiesterase (PDE) inhibitors, aiming to enhance treatment effectiveness, alleviate respiratory symptoms, and offer greater comfort for individuals experiencing chronic breathing problems. These PDE inhibitors work by blocking PDE enzymes, which in turn elevates intracellular cyclic AMP or cyclic GMP levels, thereby encouraging bronchodilation, diminishing inflammation, and boosting general respiratory function. As an illustration, in May 2024, Verona Pharma Plc, a biopharmaceutical firm from the UK, declared its readiness for the prospective U.S. introduction of ensifentrine, a pioneering dual PDE3/4 inhibitor designed for chronic obstructive pulmonary disease (COPD), which is anticipated in Q3 2024, subject to FDA approval. Ensifentrine, administered through nebulization, has demonstrated considerable decreases in COPD exacerbation rates and notable enhancements in dyspnea during Phase III trials. Verona has also secured $650 million in funding to facilitate its commercial deployment and continued development, encompassing a planned Phase II fixed-dose combination study with glycopyrrolate for ongoing COPD therapy.

Who Are The Companies Participating In The Dyspnea Market?

Major companies operating in the dyspnea market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca, Novartis AG, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Amneal Pharmaceuticals LLC, Lupin Ltd, Inogen Inc, Fisher & Paykel Healthcare, ResMed Inc, Koninklijke Philips N.V, Masimo Corporation, Breas Medical, PARI Medical Holding GmbH, BMC Medical, Hamilton Medical, Nihon Kohden Corporation, Cipla Inc

Get The Full Dyspnea Market Report:

https://www.thebusinessresearchcompany.com/report/dyspnea-global-market-report

Which Region Is The Top Contributor To The Dyspnea Market By Share?

North America was the largest region in the dyspnea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyspnea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Dyspnea Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/dyspnea-global-market-report

Browse Through More Reports Similar to the Global Dyspnea Market 2026, By The Business Research Company

Airway Stent Market Report 2026

https://www.thebusinessresearchcompany.com/report/airway-stent-global-market-report

Dysphagia Supplement Market Report 2026

https://www.thebusinessresearchcompany.com/report/dysphagia-supplement-global-market-report

Sleep Apnea Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795